TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31244352

Group type: EXPERIMENTAL
Intervention: internet-based cognitive behavioral therapy (iCBT)
Number of subjects: 181

Group type: COMPARATOR
Intervention: midwife counseling
Number of subjects: 181
Study: 29863591

Group type: EXPERIMENTAL
Intervention: BANDS
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CS + BANDS
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CS30
Number of subjects: 12

Group type: COMPARATOR
Intervention: CS (traditional set with continuous repetitions)
Number of subjects: 12
Study: 27787873

Group type: EXPERIMENTAL
Intervention: Neutrophil-to-lymphocyte ratio (NLR)
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Surgery without NAC
Number of subjects: 317
Study: 25421427

Group type: EXPERIMENTAL
Intervention: EHDHP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LHDHP
Number of subjects: 20
Study: 23578890

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 1498

Group type: COMPARATOR
Intervention: Cobalt chromium bare metal stent (BMS)
Number of subjects: 1498

Group type: EXPERIMENTAL
Intervention: Patients with stent thrombosis (ST)
Number of subjects: 1498

Group type: EXPERIMENTAL
Intervention: BMS implantation
Number of subjects: 1498

Group type: EXPERIMENTAL
Intervention: ST segment resolution of at least 70% in the EKG post-PCI
Number of subjects: 1498

Group type: EXPERIMENTAL
Intervention: High Killip class on admission
Number of subjects: 1498
Study: 22235600

Group type: EXPERIMENTAL
Intervention: Radiostethoscope
Number of subjects: 2
Study: 19606406

Group type: EXPERIMENTAL
Intervention: Olanzapine treatment
Number of subjects: 622
Study: 16386740

Group type: EXPERIMENTAL
Intervention: Back-pain-reducing program (BPRP)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 56
Study: 12754030

Group type: EXPERIMENTAL
Intervention: Topical vancomycin (500mg)
Number of subjects: 14
Study: 11003358

Group type: EXPERIMENTAL
Intervention: Basiliximab (20 mg on day 0 and day 4 posttransplantation)
Number of subjects: 722
Study: 9104973

Group type: EXPERIMENTAL
Intervention: Transmyocardial laser revascularization
Number of subjects: 200
Study: 1448311

Group type: EXPERIMENTAL
Intervention: Oral rifampin (20 mg/kg/day for 4 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical chloramphenicol
Number of subjects: 0
Study: 3887552

Group type: EXPERIMENTAL
Intervention: 1:3 jejunoileal ratio
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: 3:1 jejunoileal ratio
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Bypass surgery
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Long jejunum and short ileum segment
Number of subjects: 89
Study: 31475502

Group type: EXPERIMENTAL
Intervention: AirLoc brace
Number of subjects: 39

Group type: COMPARATOR
Intervention: Plaster cast
Number of subjects: 39
Study: 28502739

Group type: EXPERIMENTAL
Intervention: Hungry participants with social proof heuristic
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hungry participants without social proof heuristic
Number of subjects: 0
Study: 26059337

Group type: EXPERIMENTAL
Intervention: Pitavastatin 1 mg
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 24100910

Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL) method
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lecture-Based Learning (LBL) method
Number of subjects: 30
Study: 21357819

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy with a defibrillator (CRT-D) in patients with LBBB
Number of subjects: 1817

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy with a defibrillator (CRT-D) in patients with non-LBBB
Number of subjects: 1817

Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 1817
Study: 19663668

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid therapy
Number of subjects: 311
Study: 17024642

Group type: EXPERIMENTAL
Intervention: Ankle foot orthoses (AFO)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No ankle foot orthoses (without AFO)
Number of subjects: 8
Study: 14756598

Group type: EXPERIMENTAL
Intervention: Psychological adjustment
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Physical adjustment
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Age as a factor
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Personal resources (self-image, optimism, perceived control)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Social resources (social support)
Number of subjects: 287
Study: 11772140

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (25, 50, 75, and 100 microg/h, replaced every 3 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sustained-release oral morphine
Number of subjects: 0
Study: 10223542

Group type: EXPERIMENTAL
Intervention: IFN‐alpha2b (3 MU three times weekly, intramuscularly)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: IFN‐alpha2b
Number of subjects: 242
Study: 7603933

Group type: EXPERIMENTAL
Intervention: Patient education leaflet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no leaflet)
Number of subjects: 0
Study: 2204343

Group type: EXPERIMENTAL
Intervention: Enciprazine (D 13 112), dosage not specified
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enciprazine (D 13 112), highest dosage
Number of subjects: 0
Study: 533862

Group type: EXPERIMENTAL
Intervention: Victim resistance (more resistance)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Victim resistance (completed rape)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Victim resistance (attempted rape)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Sex of observer (women)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Sex of observer (men)
Number of subjects: 229
Study: 31064014

Group type: EXPERIMENTAL
Intervention: 0.05% NME (NME1)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: 0.1% NME (NME2)
Number of subjects: 432

Group type: COMPARATOR
Intervention: 0% NME (Control)
Number of subjects: 432
Study: 28301282

Group type: EXPERIMENTAL
Intervention: 20 µg hepatitis B vaccine (IM20 group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 60 µg hepatitis B vaccine (IM60 group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blank control
Number of subjects: 0
Study: 25436624

Group type: EXPERIMENTAL
Intervention: Eccentric exercise 1 (ECC1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Eccentric exercise 2 (ECC2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control sessions (no exercise)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Eccentric exercise (both ECC1 and ECC2)
Number of subjects: 16
Study: 23905376

Group type: EXPERIMENTAL
Intervention: Bushen Tiaojing Recipe (BTR) and GnRHa/FSH/hCG
Number of subjects: 66

Group type: COMPARATOR
Intervention: GnRHa/FSH/hCG
Number of subjects: 66
Study: 21492926

Group type: EXPERIMENTAL
Intervention: 6 months' open-label isoniazid followed by 30 months' masked isoniazid
Number of subjects: 1995

Group type: COMPARATOR
Intervention: 6 months' open-label isoniazid followed by 30 months' masked placebo
Number of subjects: 1995

Group type: EXPERIMENTAL
Intervention: 360 days of antiretroviral therapy
Number of subjects: 1995

Group type: EXPERIMENTAL
Intervention: Tuberculin skin test positive participants receiving continued isoniazid treatment
Number of subjects: 1995

Group type: EXPERIMENTAL
Intervention: Tuberculin skin test negative participants receiving continued isoniazid treatment
Number of subjects: 1995
Study: 19621658

Group type: EXPERIMENTAL
Intervention: 16-multidetector computed tomography (MDCT) with cholangiography and angiography
Number of subjects: 75
Study: 16717465

Group type: EXPERIMENTAL
Intervention: Early tirofiban administration (n = 32)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Late tirofiban administration (n = 34)
Number of subjects: 66
Study: 14644853

Group type: COMPARATOR
Intervention: Gym based resistance exercise programme
Number of subjects: 105

Group type: COMPARATOR
Intervention: Hydrotherapy resistance exercise programme
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Control group
Number of subjects: 105
Study: 10795728

Group type: EXPERIMENTAL
Intervention: Yohimbine (0.65 mg/kg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Clonidine (5 microg/kg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 8690832

Group type: EXPERIMENTAL
Intervention: Subjects who entered the study (528)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Hypothetical studies with different degrees of selection bias
Number of subjects: 528
Study: 2061566

Group type: EXPERIMENTAL
Intervention: Benfluorex (450 mg/day)
Number of subjects: 7
Study: 6635447

Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg once daily for three days
Number of subjects: 54

Group type: COMPARATOR
Intervention: Rifampin 600 mg plus trimethoprim 160 mg once daily for three days
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Single dose of rifampin 600 mg plus trimethoprim 160 mg
Number of subjects: 54
Study: 3842545

Group type: EXPERIMENTAL
Intervention: 2 G of salt in the morning and a placebo in the evening
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Placebo in the morning and 2 G of salt in the evening
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo at both times
Number of subjects: 216
Study: 31733583

Group type: EXPERIMENTAL
Intervention: SB-20M culture medium for morphological identification of S. mutans
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: SB-20M culture medium for morphological identification of S. sobrinus
Number of subjects: 266

Group type: COMPARATOR
Intervention: Biochemical identification (biotyping) and proteomic identification by MALDI-TOF mass spectrometry
Number of subjects: 266
Study: 30527827

Group type: EXPERIMENTAL
Intervention: Repeated testing (7 quizzes over one academic year)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no quizzes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Survey responses
Number of subjects: 0
Study: 27098818

Group type: EXPERIMENTAL
Intervention: Nintendo wii (NW) gaming
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Conventional therapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control
Number of subjects: 105
Study: 24607708

Group type: EXPERIMENTAL
Intervention: Prone Maximum Restraint (PMR) position
Number of subjects: 10

Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 10

Group type: COMPARATOR
Intervention: Seated position
Number of subjects: 10
Study: 22437792

Group type: EXPERIMENTAL
Intervention: Oral recombinant salmon calcitonin (rsCT) tablets (0.2 mg/d) plus placebo nasal spray
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Synthetic salmon calcitonin (ssCT) nasal spray (200 IU/d) plus placebo tablets
Number of subjects: 565

Group type: COMPARATOR
Intervention: Placebo (placebo tablets plus placebo nasal spray)
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Oral recombinant salmon calcitonin (rsCT) tablets
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 565
Study: 21331988

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed guar gum
Number of subjects: 61

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 61
Study: 18333888

Group type: EXPERIMENTAL
Intervention: PHX1149 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PHX1149 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PHX1149 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15747700

Group type: EXPERIMENTAL
Intervention: Lateral approach nerve block
Number of subjects: 60

Group type: COMPARATOR
Intervention: Posterior approach nerve block
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 60
Study: 12556153

Group type: EXPERIMENTAL
Intervention: Neurolysis (nerve release)
Number of subjects: 500000

Group type: COMPARATOR
Intervention: Control cohort (no intervention)
Number of subjects: 500000
Study: 10371259

Group type: EXPERIMENTAL
Intervention: Alcohol day (0.35 g/kg of 95% alcohol)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo day (1 ml of alcohol in 240 ml beverages)
Number of subjects: 26
Study: 8877028

Group type: EXPERIMENTAL
Intervention: gamma‐L‐glutamyl‐5‐hydroxy‐L‐tryptophan (glu‐5‐HTP)
Number of subjects: 9

Group type: COMPARATOR
Intervention: gamma‐L‐glutamyl-L‐tryptophan (glu‐TRP)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 1673736

Group type: EXPERIMENTAL
Intervention: Continued antiepileptic treatment
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Slow withdrawal of antiepileptic treatment
Number of subjects: 1013
Study: 6873851

Group type: EXPERIMENTAL
Intervention: Dolo Visano Supp. sine codeino
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dolo Visano Supp. (with codeine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference preparation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both new suppository preparations
Number of subjects: 0
Study: 30219772

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 3492

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 3492

Group type: EXPERIMENTAL
Intervention: All-bari-RA (any baricitinib dose)
Number of subjects: 3492
Study: 29503371

Group type: EXPERIMENTAL
Intervention: Facial exercises program (30 min, twice a week for 12 weeks)
Number of subjects: 75
Study: 27177079

Group type: EXPERIMENTAL
Intervention: Group schema therapy (ST)
Number of subjects: 42
Study: 25493600

Group type: EXPERIMENTAL
Intervention: Triple maternal antiretrovirals (zidovudine, lamivudine, and either nevirapine, nelfinavir, or lopinavir-ritonavir)
Number of subjects: 1479

Group type: COMPARATOR
Intervention: Daily infant nevirapine
Number of subjects: 1479
Study: 22377796

Group type: EXPERIMENTAL
Intervention: Black currant anthocyanins (BCACs) 50 mg/day (n = 19)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (n = 19)
Number of subjects: 38
Study: 19700304

Group type: COMPARATOR
Intervention: Sustained-release oral oxycodone 20mg followed by immediate-release oxycodone 10mg 6-hourly for the first 24h (group O)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 100mug (group I)
Number of subjects: 120
Study: 18355324

Group type: EXPERIMENTAL
Intervention: Saxagliptin (low-dose cohort: 2.5, 5, 10, 20 or 40 mg once daily for 12 weeks)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Saxagliptin (high-dose cohort: 100 mg once daily for 6 weeks)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Saxagliptin (both cohorts)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study: 15821191

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 93
Study: 12425782

Group type: EXPERIMENTAL
Intervention: Educational outreach visits by pharmacists
Number of subjects: 102
Study: 10802002

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 35
Study: 8894886

Group type: EXPERIMENTAL
Intervention: Primary nursing
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 161
Study: 1800760

Group type: EXPERIMENTAL
Intervention: Labetalol 100 mg twice daily (n = 30)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 25 mg twice daily (n = 31)
Number of subjects: 61
Study: 6331783

Group type: EXPERIMENTAL
Intervention: Cimetidine (32 patients)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (39 patients)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cimetidine (10 patients with gastric ulcer)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (12 patients with gastric ulcer)
Number of subjects: 72
Study: 12529075

Group type: EXPERIMENTAL
Intervention: Caffeine (4.0 mg/kg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo caffeine
Number of subjects: 42
Study: 29995947

Group type: EXPERIMENTAL
Intervention: Intra-dialytic low-frequency electrical muscle stimulation (LF-EMS)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Intra-dialytic cycling
Number of subjects: 64

Group type: COMPARATOR
Intervention: Non-exercise control
Number of subjects: 64
Study: 27167369

Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN) combined with rehabilitation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rehabilitation alone
Number of subjects: 20
Study: 24815571

Group type: EXPERIMENTAL
Intervention: Community engagement and service-strengthening intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 0
Study: 22185894

Group type: EXPERIMENTAL
Intervention: Combined sleep hygiene education and behavioral approach program (30 min) including relaxation training, stimulus control, and sleep restriction.
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 2
Study: 20420475

Group type: EXPERIMENTAL
Intervention: Step‐down model (CP) consisting of initial short‐term day hospital treatment followed by conjoint group and individual outpatient treatment
Number of subjects: 114

Group type: COMPARATOR
Intervention: Outpatient individual psychotherapy (OIP)
Number of subjects: 114
Study: 19105001

Group type: EXPERIMENTAL
Intervention: Chaplain interventions (5 visits, average total visit time 44 min)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (no chaplain visits)
Number of subjects: 166
Study: 16062017

Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg orally) followed by misoprostol (800 micro gm intravaginally)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Methotrexate (50 mg/m2 intramuscularly) followed by misoprostol (800 micro gm intravaginally)
Number of subjects: 100
Study: 12231310

Group type: EXPERIMENTAL
Intervention: Opegan (low-molecular-weight sodium hyaluronate 1%)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Healon (high-molecular-weight sodium hyaluronate 1%)
Number of subjects: 136
Study: 10202166

Group type: EXPERIMENTAL
Intervention: Cisplatin (40 mg/m² once a week for up to six doses during radiotherapy)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 369
Study: 7599666

Group type: EXPERIMENTAL
Intervention: Continuous oral bromocriptine (2.5-10.0 mg/day) during two consecutive 30-day periods (T-1 and T-2)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intermittent oral bromocriptine (from day 1 to 15 of each 30-day period)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control period (no treatment)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups (1 and 2) after treatment
Number of subjects: 14
Study: 2403953

Group type: EXPERIMENTAL
Intervention: Medium-sized adenomas
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: Large adenomas
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: Villous A adenomas
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: Villous B adenomas
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: Villous C and D adenomas
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: Left-sided location of adenomas
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: Multiplicity of adenomas
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: Age greater than or equal to 60 years
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: Gender (men)
Number of subjects: 1867
Study: 318952

Group type: EXPERIMENTAL
Intervention: Spironolactone (400 mg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (100 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 24
Study: 31177924

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg rectal)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Glycerin suppository (placebo)
Number of subjects: 100
Study: 28947465

Group type: EXPERIMENTAL
Intervention: Continuous hyperosmolar therapy (20% NaCl) plus standard care
Number of subjects: 370

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 370
Study: 25032123

Group type: EXPERIMENTAL
Intervention: N‐acetyl‐cysteine (NAC) (1200 mg/day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ginseng (200 mg/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no antioxidant drugs)
Number of subjects: 48
Study: 23424164

Group type: EXPERIMENTAL
Intervention: Mirabegron 100 mg BID
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Mirabegron 150 mg BID
Number of subjects: 314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Tolterodine 4 mg ER
Number of subjects: 314
Study: 19952809

Group type: EXPERIMENTAL
Intervention: Ibuprofen topical gel
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 106
Study: 18511165

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for 4 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (sleep hygiene education only)
Number of subjects: 24
Study: 16570267

Group type: EXPERIMENTAL
Intervention: Eating Disorder (ED) memoir
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control memoir
Number of subjects: 50
Study: 14528947

Group type: EXPERIMENTAL
Intervention: New automatic matching procedure using chamfer matching with additional information on gradient angle and magnitude of edges
Number of subjects: 29

Group type: COMPARATOR
Intervention: Regular chamfer matching
Number of subjects: 29
Study: 11228952

Group type: EXPERIMENTAL
Intervention: Mirror therapy
Number of subjects: 1
Study: 9201012

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including in-hospital counseling, smoking cessation videotape, self-help literature, nicotine replacement therapy, and 3 months of telephone follow-up
Number of subjects: 324

Group type: COMPARATOR
Intervention: Self-help literature and brief counseling lasting 10 minutes
Number of subjects: 324
Study: 8067229

Group type: EXPERIMENTAL
Intervention: Morphine + Ephedrine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 32